CurrentUnitedHealthcarePolicy CS081KY.06

Nerve Graft Restore Erectile Function Radical Prostatectomy Ky Cs

UnitedHealthcare Kentucky medical policy on autologous or allogenic nerve grafts (e.g., sural nerve) to restore erectile function during or after radical prostatectomy, addressing medical necessity, evidence, applicable procedure codes, and related guidance for Kentucky members.

Policy Summary

PayerUnitedHealthcare

PolicyNerve Graft Restore Erectile Function Radical Prostatectomy Ky Cs

Policy CodePolicy CS081KY.06

Change TypeSupporting information updated (Description of Services, Clinical Evidence, References)

Effective DateNov 1, 2024

Next Review Date

Key ActionWhen deciding coverage, reference member-specific benefit plan documents and applicable federal/state/contractual requirements; inclusion of a code in the policy does not imply coverage or guarantee payment.

SourceLink

POLICY UPDATE CHANGES

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.

1State-specific policy (Kentucky)

2Referenced CPT unlisted codes

0Covered indications (per policy)

Coverage Summary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

This policy addresses autologous or allogenic nerve grafting (for example, sural nerve grafts) proposed to restore erectile function during or after radical prostatectomy. The policy covers the UnitedHealthcare Kentucky scope for this service. Policy stance: Not covered — cosmetic / not medically necessary. Effective date: 2024-11-01; Last review: 2024-11-01.

Medical-Necessity Criteria

Coverage Rationale / Medical Necessity

Autologous or allogenic nerve grafts to restore erectile function during or after radical prostatectomy are considered:

Autologous (e.g., sural) or allogenic nerve grafts to restore erectile function during or after radical prostatectomy are unproven and not medically necessary due to insufficient evidence of efficacy.

Not Medically Necessary / Cosmetic

Coverage stance: Not covered (cosmetic / not medically necessary). Autologous (e.g., sural) or allogenic nerve grafts to restore erectile function during or after radical prostatectomy are considered unproven and not medically necessary because available evidence is insufficient to demonstrate consistent efficacy. The clinical literature consists mainly of case series and retrospective studies with mixed results and potential bias, and randomized data are limited and did not show clear benefit; professional guidelines do not endorse nerve grafting as an effective replacement for widely resected neurovascular bundles.

Applicable Procedure Codes (reference only)

Applicable Procedure Codes (reference only)CPT

55899	Unlisted procedure, male genital system
64999	Unlisted procedure, nervous system

Documentation Required

Reference policy for coverage determinations

When deciding coverage, reference member-specific benefit plan documents and applicable federal/state/contractual requirements; inclusion of a code in the policy does not imply coverage or guarantee payment.

55899
64999

Background and Evidence Summary

Background: Nerve grafting (most commonly sural nerve grafting) has been proposed to bridge resected cavernous nerves during radical prostatectomy to restore spontaneous erectile function when nerve-sparing is not possible. The rationale is to replace or reconstruct damaged cavernous nerves to improve erectile function outcomes.

Types of evidence and limitations: Evidence consists primarily of single-arm case series, retrospective observational studies, and small prospective cohorts that report mixed results and are limited by lack of control groups, small sample sizes, baseline differences between groups, and potential bias. A randomized trial was stopped early for lack of benefit at interim analysis, and systematic reviews note the absence of high-quality comparative data.

Overall conclusion: Because higher-quality randomized evidence is limited and available randomized data did not demonstrate consistent improvement, nerve grafting for restoration of erectile function after radical prostatectomy remains unproven and more rigorous trials are needed to establish clinical efficacy and inform practice.

Evidence Type	Summary
Randomized trial	One randomized trial (Davis et al. 2009) was terminated early after interim analysis showed no benefit of unilateral sural nerve grafting versus control; study did not demonstrate improved potency at two years.
Observational studies	Multiple case series and retrospective/prospective observational studies report mixed results with some improvements noted but are limited by lack of control groups, small samples, and potential bias.
Guideline position	NCCN states replacement of resected nerves with nerve grafts does not appear effective for wide resections (2022; updated 2024); AUA 2018 does not endorse nerve grafting as a standard ED treatment.

Definitions

Sural nerve graft (SNG)Autologous nerve graft harvested from the sural nerve used to bridge resected cavernous nerves during radical prostatectomy.

Radical prostatectomy (RP/RRP/RARP)Surgical removal of the prostate for localized prostate cancer; variants include radical retropubic prostatectomy (RRP) and robot-assisted radical prostatectomy (RARP).

Provider Actions & Billing Guidance

Denial Risk

Not covered — nerve grafting to restore erectile function

Autologous or allogenic nerve grafting to restore erectile function during or after radical prostatectomy is considered unproven and not medically necessary due to insufficient evidence of efficacy. Claims for these procedures (e.g., CPT 55899, 64999) may be denied per the policy’s coverage rationale.

55899
64999